Pacific Edge (Pacific Edge) Growth Rank : 0 (As of Jun. 21, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Pacific Edge Growth Rank?

Pacific Edge has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Pacific Edge Growth Rank Related Terms

Thank you for viewing the detailed overview of Pacific Edge's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Edge (Pacific Edge) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pacific Edge Ltd (OTCPK:PFGTF) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

PEB:New Zealand PEB:Australia

Address

87 St David Street, P.O. Box 56, Dunedin, STL, NZL, 9016

Website

https://www.pacificedgedx.com

Pacific Edge Ltd is a NewZealand based company involved in developing and commercializing diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. The company operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses world wide; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, New Zealand, and the Rest of the World.